Skip to main content
European Commission logo print header
Contenu archivé le 2024-04-15

HEPATITIS B SURFACE ANTIGEN PARTICLE AS A CARRIER FOR PRESENTATION OF FOOT AND MOUTH DISEASE VIRUS ANTIGENS

Objectif

OBTAIN COMPLEX ANTIGENS ALLOWING THE DEVELOPMENT OF IMMUNITY AGAINST FOOT AND MOUTH DISEASE VIRUS, AND MAY BE OBTENTION OF A SAFE AND CHEAPER VACCINE AGAINST FOOT AND MOUTH DISEASE.
The project aimed at the synthesis in baker's yeast of a hybrid virus like particle comprising the surface antigen of the virus which caused hepatitis B in man, and part of a surface protein from foot and mouth disease virus (FMDV). Many yeast strains were genetically engineered by recombinant deoxyribonucleic acid (DNA) techniques, producing hybrid virus like particles in which the FMDV portion was present at different sites. It is hoped that these studies will shed light on the question of which parts of the FMDV are essential and how they must be presented to the immune system, in order to protect target animals against the disease.
THE OBJECTIVE OF THE PROGRAMME IS TO DEVELOP A HIGHLY IMMUNOGENIC COMPLEX CONTAINING FMDV ANTIGENIC DETERMINANTS AGAINST DIFFERENT TYPES OF THE VIRUS.THE POLYVALENT SUB-UNIT VACCINE WILL BE PRODUCED BY RECOMBINANT DNA TECHNIQUES, ASSOCIATING FMVD ANTIGENIC DETERMINANTS WITH HEPATITIS B SURFACE ANTIGENS. THESES RECOMBINANT PARTICLES WILL BE EXPRESSED IN YEAST OR ANIMAL CELLS, AND ANALYSED FOR THEIR IMMUNOLOGICAL PROPERTIES.

Thème(s)

Data not available

Appel à propositions

Data not available

Régime de financement

CSC - Cost-sharing contracts

Coordinateur

Wellcome Foundation Ltd
Contribution de l’UE
Aucune donnée
Adresse
Langley Court
BR3 3BS Beckenham
Royaume-Uni

Voir sur la carte

Coût total
Aucune donnée

Participants (2)